Skip to content

Search

COCOON: Virus transmission, immunity, and family wellbeing during COVID-19

The delay in community transmission of the new Coronavirus in WA, together with the strict, social distancing measures that have been adopted, provide us with an opportunity to observe the level of immunity development to the virus within the community and assess the impact of COVID-19 pandemic on health and well-

Funding boost for cancer, antimicrobial resistance, and pain management treatments

The Kids Research Institute Australia researchers will share in $2.3 million awarded by the Western Australian Department of Health Innovation Seed Fund.

Global participatory wastewater surveillance to understand mpox clade diversity in war and conflict-affected countries

War and conflict severely disrupt public health systems, compromising infectious disease surveillance in many affected regions. Mpox, a re-emerging zoonotic disease, poses a growing global threat, especially in areas where traditional monitoring is inaccessible.The mpox virus has distinct clades with varying transmission and severity.

Tracking Plasmodium knowlesi through faecal DNA for monitoring zoonotic transmission in wild macaques across Southeast and South Asia

We conducted the non-invasive surveillance of Plasmodium knowlesi in wild macaques using 4,752 faecal samples collected across nine endemic countries. 

Treatment with inhaled aerosolised ethanol reduces viral load and potentiates macrophage responses in an established influenza mouse model

Treatment options for viral lung infections are currently limited. We aimed to explore the safety and efficacy of inhaled ethanol in an influenza-infection mouse model.

Immune checkpoint therapy responders display early clonal expansion of tumor infiltrating lymphocytes

Immune checkpoint therapy (ICT) causes durable tumour responses in a subgroup of patients, but it is not well known how T cell receptor beta (TCRβ) repertoire dynamics contribute to the therapeutic response. 

Early treatment with fluvoxamine, bromhexine, cyproheptadine, and niclosamide to prevent clinical deterioration in patients with symptomatic COVID-19: a randomized clinical trial

Repurposed drugs with host-directed antiviral and immunomodulatory properties have shown promise in the treatment of COVID-19, but few trials have studied combinations of these agents. The aim of this trial was to assess the effectiveness of affordable, widely available, repurposed drugs used in combination for treatment of COVID-19, which may be particularly relevant to low-resource countries. 

Compound Repurposing Into Novel Therapeutics In COVID-19 At risk Lungs (CRITICAL Study)

Anthony Christopher David Ingrid Shannon Thomas Kicic Blyth Martino Laing Simpson Iosifidis BSc (Hons) PhD MBBS (Hons) DCH FRACP FRCPA PhD BSc PhD

An infant mouse model of influenza-driven nontypeable Haemophilus influenzae colonization and acute otitis media suitable for preclinical testing of novel therapies

Nontypeable Haemophilus influenzae (NTHi) is a major otitis media (OM) pathogen, with colonization a prerequisite for disease development. Most acute OM is in children <5 years old, with recurrent and chronic OM impacting hearing and learning. Therapies to prevent NTHi colonization and/or disease are needed, especially for young children. Respiratory viruses are implicated in driving the development of bacterial OM in children.

Pseudomonas aeruginosa modulates neutrophil granule exocytosis in an in vitro model of airway infection

A population of neutrophils recruited into cystic fibrosis (CF) airways is associated with proteolytic lung damage, exhibiting high expression of primary granule exocytosis marker CD63 and reduced phagocytic receptor CD16. Causative factors for this population are unknown, limiting intervention. Here we present a laboratory model to characterize responses of differentiated airway epithelium and neutrophils following respiratory infection.